The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

London-based drugmaker GSK has announced the UK approval of Nucala (mepolizumab) as an add-on maintenance biologic treatment ...

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...

Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled ...

Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, having a cold or respiratory infection can temporarily make it harder ...

(StatePoint) More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This ...

Misunderstanding COPD and asthma can be risky. Recognising the difference in the condition, treatment options, and the need ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...